4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
4D Molecular Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -226.0%. For fiscal 2025 it was -187.2%, against -507678.4% the year before. The highest annual figure on record is -187.2% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -187.2% | +507491.1 |
| FY2024 | Dec 31, 2024 | -507678.4% | −507133.7 |
| FY2023 | Dec 31, 2023 | -544.6% | +2971.9 |
| FY2022 | Dec 31, 2022 | -3516.5% | −3121.1 |
| FY2021 | Dec 31, 2021 | -395.5% | +20.8 |
| FY2020 | Dec 31, 2020 | -416.3% | +310.4 |
| FY2019 | Dec 31, 2019 | -726.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1959.4% | +66023.9 |
| Q2 FY2026 | Jun 30, 2026 | -2037.2% | +394336.2 |
| Q1 FY2026 | Mar 31, 2026 | -2416.1% | +380591.0 |
| Q4 FY2025 | Dec 31, 2025 | 17.3% | +5611717.3 |
| Q3 FY2025 | Sep 30, 2025 | -67983.3% | +1636416.7 |
| Q2 FY2025 | Jun 30, 2025 | -396373.3% | +452746.7 |
| Q1 FY2025 | Mar 31, 2025 | -383007.1% | −246807.1 |
| Q4 FY2024 | Dec 31, 2024 | -5611700.0% | −5611630.8 |
| Q3 FY2024 | Sep 30, 2024 | -1704400.0% | −1690954.0 |
| Q2 FY2024 | Jun 30, 2024 | -849120.0% | −839017.3 |
| Q1 FY2024 | Mar 31, 2024 | -136200.0% | −133896.9 |
| Q3 FY2023 | Sep 30, 2023 | -69.2% | +5229.8 |
| Q2 FY2023 | Jun 30, 2023 | -13446.0% | +4100.9 |
| Q1 FY2023 | Mar 31, 2023 | -10102.7% | −7937.6 |
| Q4 FY2022 | Dec 31, 2022 | -2303.1% | +24614.3 |
| Q3 FY2022 | Sep 30, 2022 | -5299.0% | −3640.1 |
| Q2 FY2022 | Jun 30, 2022 | -17546.9% | −17494.8 |
| Q1 FY2022 | Mar 31, 2022 | -2165.1% | −1349.5 |
| Q4 FY2021 | Dec 31, 2021 | -26917.4% | −26812.1 |
| Q3 FY2021 | Sep 30, 2021 | -1658.9% | −1241.9 |
| Q2 FY2021 | Jun 30, 2021 | -52.1% | +323.5 |
| Q1 FY2021 | Mar 31, 2021 | -815.6% | – |
| Q3 FY2020 | Sep 30, 2020 | -105.3% | – |
| Q2 FY2020 | Jun 30, 2020 | -417.0% | – |
| Q1 FY2020 | Mar 31, 2020 | -375.6% | – |
See a number that looks wrong?